PGRMC1: a new biomarker for the estrogen receptor in breast cancer

doi:10.1186/bcr2191

Breast Cancer Research

Volume 10
Issue 6

Viewing options:

Abstract
Full text
PDF (42KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Craven RJ

on PubMed

Craven RJ
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Editorial

PGRMC1: a new biomarker for the estrogen receptor in breast cancer

Rolf J Craven

Department of Molecular and Biomedical Pharmacology, Markey Cancer Center, University of Kentucky, MS-305 UKMC, Lexington, KY 40536, USA

author email corresponding author email

Breast Cancer Research 2008, 10:113doi:10.1186/bcr2191


Published:	24 November 2008

See related research article by Neubauer et al., http://breast-cancer-research.com/content/10/5/R85

Abstract

Estrogen receptor (ER) status is a critical biomarker in breast cancer, in large part because the ER is the target of tamoxifen and similar drugs. In the previous issue of Breast Cancer Research, Neubauer and colleagues used a proteomic approach to identify proteins that are differentially regulated by ER in breast tumors. The authors showed that ER-negative tumors have elevated levels of PGRMC1 (progesterone receptor membrane component-1), a hormone receptor component and binding partner for P450 proteins. In contrast, PGRMC1 was phosphorylated in ER-positive tumors. The staining patterns of ER and PGRMC1 were mutually exclusive in breast tumor sections, and PGRMC1 staining was sharply increased in hypoxic areas of the tumor. The results suggest that PGRMC1 is a candidate biomarker for ER status and hypoxia in breast cancer.